Travere Therapeutics, INC Form 4 insider transactions

Director Timothy Coughlin reports acquisition of shares and stock options in Travere Therapeutics under the company's equity incentive plan.

Director Suzanne Bruhn reported acquiring 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics, Inc. on May 8, 2024, as part of the company's equity incentive plan.

Director Roy D. Baynes reported acquiring shares and stock options in Travere Therapeutics, Inc. on May 8, 2024, according to a Form 4 filing.

Christopher R. Cline, CFO of Travere Therapeutics, sold 54 shares of common stock on April 11, 2024, to cover tax withholding obligations related to vested restricted stock units.